Antibody Responses to Hepatitis A Virus Vaccine in HIV-Infected Children with Evidence of Immunologic Reconstitution while Receiving Highly Active Antiretroviral Therapy

BackgroundHuman immunodeficiency virus (HIV)–infected patients have weak responses to vaccines and may require revised immunization regimens. We investigated the safety and immunogenicity of 2 doses of hepatitis A virus (HAV) vaccine followed by a booster dose in HIV-infected children receiving stable highly active antiretroviral therapy MethodsA total of 235 children with CD4+ T cell percentages ⩾20% received 2 vaccine doses 24 weeks apart, and 117 received a third vaccine dose after 104 weeks. Anti-HAV antibody titers were measured at baseline and at 32, 104, and 112 weeks after the first vaccination. Subjects with antibody titers ⩾20 mIU/mL were defined as being seropositive. High and low antibody responses were defined as titers ⩾250 and